Log in to search using one of your social media accounts:

 

FDA approves Technivie for treatment of chronic hepatitis C genotype 4

The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).
Source: Food and Drug Administration - Category: American Health Source Type: news

Related Links:

CONCLUSIONS: The +49G allele confers susceptibility to HCV infection and with male gender, both in chronic disease. In addition, the -319C/+49G haplotype confers susceptibility to HCV genotype 3 infection. Our results support an important role of the -319 C/T and +49 A/G polymorphisms in HCV infection. PMID: 29033194 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
Summary BackgroundWith the development of direct‐acting anti‐virals (DAAs), almost all patients with chronic hepatitis C virus (HCV) infection can achieve sustained viral response (SVR). AimTo evaluate the short‐term risk of HCC among patients with SVR by DAAs, including those with cirrhosis or previous HCC. MethodsThis large‐scale, multicentre cohort study included 1,675 consecutive patients who achieved SVR by treatment with interferon‐free sofosbuvir‐based regimens, divided into groups with (n = 152) or without previous HCC (n = 1,523). The Kaplan‐Meier method and Cox proportional hazar...
Source: Alimentary Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Prabha Desikan, Zeba KhanIndian Journal of Medical Microbiology 2017 35(3):332-339Hepatitis B virus (HBV) and hepatitis C virus (HCV) have several important similarities including worldwide distribution, hepato-tropism, similar modes of transmission and the ability to induce chronic infection that may lead to liver cirrhosis and hepatocellular carcinoma. Since both viruses are individually known to cause the pathologies mentioned above, co-infection with both HBV and HCV would be expected to be linked with higher morbidity as well as mortality and impact healthcare resource utilisation. Precise estimate of the prevalence o...
Source: Indian Journal of Medical Microbiology - Category: Microbiology Authors: Source Type: research
In this study, we have investigated the host genetic variations inIFNL loci to determine the association ofIFNL3/4 polymorphisms with HCV SC and baseline VLs in a Vietnamese HCV-seropositive cohort. The majority of the cohort harboured major homozygous polymorphisms inIFNL3/4 cluster (i.e. rs12979860-CC: 82.7%; rs8099917-TT: 84.8% and rs368234815-TT/TT: 85.5%) and the SC rates in these groups were 15.8%, 16.3% and 15.7%, respectively. In the minor allele groups, the resolution rates were lower (12% in rs12979860 non-CC, 9.1% in rs8099917 non-TT and 9.5% in rs368234815 non-TT/TT). Furthermore, in individuals harbouring mino...
Source: Archives of Virology - Category: Virology Source Type: research
Conclusion: HCV treatment was highly effective among HIV‐infected patients who received care within an integrated nurse/pharmacist adherence support program. These results suggest that race and psychosocial comorbidity may not be barriers to HCV elimination. (Hepatology 2017).
Source: Hepatology - Category: Internal Medicine Authors: Tags: Viral Hepatitis Source Type: research
Publication date: Available online 10 October 2017 Source:Pharmacology & Therapeutics Author(s): Ulrich Spengler Hepatitis C virus (HCV) is a global health problem, because infection frequently leads to chronic hepatitis C eventually progressing to liver cirrhosis and liver cancer. Improved insights into the HCV replication cycle and the role of HCV non-structural proteins has recently enabled to identify drugs directly acting on specific HCV target structures. Agents from three drug classes have been developed and approved by the health authorities. Combinations of two or more drugs from different classes achieve hig...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Summary BackgroundHepatitis B virus (HBV)/hepatitis C virus (HCV) confection has been rarely studied in nonasian series. AimTo compare the characteristics of HBV/HCV coinfected patients to those of HBV‐ or HCV‐monoinfected patients in the ANRS CO22 HEPATHER cohort study. Patients and MethodsOf the 20 936 included patients, 95 had HBV/HCV coinfection (hepatitis B surface antigen, anti‐HCV antibody and HCV RNA positive) and were matched with 375 HBV‐ and 380 HCV‐monoinfected patients on age, gender and time since HBV or HCV diagnosis. ResultsF3‐F4 fibrosis was more frequent in coinfected patients (58%) than in HBV‐ (32%, P
Source: Alimentary Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians. A 58-year-old man is evaluated in follow-up for hepatitis C-related cirrhosis that is complicated by nonbleeding small esophageal varices and ascites. His ascites has recently worsened and has required large-volume paracentesis three times per month. He has been on a low-salt diet, spironolactone, and furosemide. On physical examination, temperature is 36.8 °C (98.2 °F), blood pressure is 98/60 mm Hg, pulse rate is 65/min, and respiration rate is 16/min; BMI is 26. He appears chronically ill. Scl...
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions Gastroenterology Hospital-Based Medicine Surgery Source Type: blogs
Conclusion In this interferon-free era, PegIFN-based regimens remain a safe and effective option for selected HCV patients.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
This study aims to characterize patients initiating OPrD± RBV and assess sustained virological response (SVR). A retrospective cohort study was performed using the database of Maccabi Healthcare Services (MHS), a 2‐million‐member health plan in Israel. The study population included adults who initiated OPrD±RBV through December 2015 per health basket criteria. A gap in medication fills (>14 days between a fill's run‐out and the next fill) was used to estimate adherence. SVR was defined by the viral tests at least 12 weeks post‐treatment. The study population consisted of 403 patients (56.3% male), ...
Source: Journal of Viral Hepatitis - Category: Infectious Diseases Authors: Tags: Original Article Source Type: research
More News: American Health | Cirrhosis | Food and Drug Administration (FDA) | Hepatitis | Hepatitis C | Liver | Norvir | Urology & Nephrology